First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
The plan is to advance innovative therapies to drug-resistant cancers
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Deputy Mayor from Addis Ababa (Ethiopia) battled out a rare laryngeal cancer at Yashoda Hospitals Hyderabad
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
Subscribe To Our Newsletter & Stay Updated
